REC-994

DB15616InvestigationalSmall molecule

REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

Code names
REC-994

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of REC-994, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In